News
- Author:
- Daniel M. Keller
Publish date: June 3, 2016
Key clinical point: Liraglutide suppresses glucagon and ketogenesis in fasting patients with type 1 diabetes.
Major finding: FFA increase was 60% ...
News
- Author:
- Daniel M. Keller
Publish date: June 3, 2016
Key clinical point: Liraglutide suppresses glucagon and ketogenesis in fasting patients with type 1 diabetes.
Major finding: FFA increase was 60% ...
News
- Author:
- Daniel M. Keller
Publish date: June 2, 2016
News
- Author:
- Daniel M. Keller
Publish date: June 2, 2016
News
- Author:
- Daniel M. Keller
Publish date: June 2, 2016
News
- Author:
- Daniel M. Keller
Publish date: May 27, 2016
News
- Author:
- Daniel M. Keller
Publish date: May 27, 2016
News
- Author:
- Daniel M. Keller
Publish date: May 25, 2016
Key clinical point: ASCT bested bortezomib for newly diagnosed younger multiple myeloma patients.
News
- Author:
- Daniel M. Keller
Publish date: May 20, 2016
Key clinical point: Precision drug targeting in phase I trials may yield efficacy information.
Major finding: Genomic targeting yielded a 42% resp...
News
- Author:
- Daniel M. Keller
Publish date: May 20, 2016
Key clinical point: Cetuximab and bevacizumab have differential effects on overall survival and progression-free survival in metastatic colon canc...
News
- Author:
- Daniel M. Keller
Publish date: April 28, 2016
News
- Author:
- Daniel M. Keller
Publish date: April 22, 2016
Key clinical point: Two oral bacteria are associated with increased pancreatic cancer risk.
Major finding: Bacteria are linked to over 50% increas...
News
- Author:
- Daniel M. Keller
Publish date: April 21, 2016
Key clinical point: Rare Merkel cell carcinoma responds well to immunotherapy with pembrolizumab.
Major finding: The response rate was 56%, all oc...
News
- Author:
- Daniel M. Keller
Publish date: April 20, 2016
Key clinical point: MammaPrint bests Adjuvant!
News
- Author:
- Daniel M. Keller
Publish date: April 19, 2016
Key clinical point: Entrectinib showed antitumor activity including intracranial responses.
